ANL

Accretion Nutraveda Ltd.

Listed SME BSE
🔥🔥🔥🔥🔥

Accretion Nutraveda Ltd. is an Ahmedabad-based manufacturer of Ayurvedic and Nutraceutical products raising approximately ₹24.77 crores through a Book Build SME IPO listed on BSE SME.

Price Band
₹122–₹129
Lot Size
1000 shares
Issue Size
₹24.77 Cr
Open Date
28 Jan
Close Date
30 Jan
Allotment
02 Feb
Listing Date
04 Feb
Min Investment
₹1,29,000

Overview

About the Company

Incorporated in 2021, Accretion Nutraveda Ltd. is a Gujarat-based company engaged in the manufacturing of Ayurvedic and Nutraceutical products. Its product portfolio spans multiple dosage forms including tablets, capsules, oral liquids, powders, oils, balms, creams, and gels. The company caters to both domestic and international markets, exporting to countries such as Sri Lanka, Singapore, and the USA. Its offerings cover therapeutic areas including liver care, women's health, bone and joint health, cognitive support, and respiratory wellness. The company operates a 10,763 sq. ft. manufacturing facility in Gujarat equipped with modern infrastructure and quality control systems.

Company Details

Founded
2021
Headquarters
Ahmedabad, Gujarat
Industry
Ayurvedic and Nutraceutical Products Manufacturing
Promoter
Mr. Mayur Popatlal Sojitra, Mr. Ankurkumar Shantilal Patel, Mr. Paraskumar Vinubhai Parmar, Mr. Hardik Mukundbhai Prajapati, Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel

📋 Objects of Issue (Use of Proceeds)

  • › Acquiring machinery for automation at the existing manufacturing facility (₹4.22 crores)
  • › Procuring machinery for setting up a new manufacturing unit (₹8.03 crores)
  • › Meeting working capital requirements of the company (₹5.50 crores)
  • › General corporate purposes

✅ Strengths

  • ✓ Diversified product range spanning multiple Ayurvedic and Nutraceutical dosage forms, catering to a broad customer base
  • ✓ Presence in both domestic and international markets, including exports to Sri Lanka, Singapore, and the USA
  • ✓ Modern 10,763 sq. ft. manufacturing facility in Gujarat with robust quality control infrastructure
  • ✓ Strong revenue growth, with income rising from ₹3.07 crores in FY2023 to ₹16.06 crores in FY2025
  • ✓ High return on equity of 81.22% and healthy EBITDA margin of 22.79% in FY2025

⚠️ Risks

  • ! The company was incorporated only in 2021, indicating a limited operating history compared to established peers
  • ! Revenue is still relatively modest compared to listed peers such as Influx Healthtech (₹104.99 Cr.) and Walpar Nutritions (₹60.26 Cr.)
  • ! Dependence on a single manufacturing facility in Gujarat exposes the company to concentration risk
  • ! The Ayurvedic and Nutraceutical sector is highly competitive and regulated, with evolving compliance requirements
  • ! International revenue exposure may be subject to currency and geopolitical risks